HCPCS Code Applications and Approvals: July 2022
Quarterly archive · CMS Level II HCPCS18 coding decisions from the First Quarter 2022 CMS cycle
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the First Quarter 2022 coding cycle, which took effect July 1, 2022.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
July 2022
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9596 | Illuccix Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | Telix Pharmaceuticals (US), Inc. | — | Establish | |
| A9601 | TAUVID Flortaucipir f 18 injection, diagnostic, 1 millicurie | Eli Lilly Intravenous | — | Establish | |
| C9090 | RYPLAZIM Injection, plasminogen, human-tvmh, 1 mg | Kedrion Biopharma Inc. Intravenous | Replaced byJ2998 | Discontinue | |
| C9091 | FYARROTM Injection, sirolimus protein-bound particles, 1 mg | Aadi Intravenous | Replaced byJ9331 | Discontinue | |
| C9092 | XIPERE Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg | Bausch & Lomb | Replaced byJ3299 | Discontinue | |
| C9093 | SUSVIMO Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg | Genentech Intravitreal | Replaced byJ2779 | Discontinue | |
| J0739 | APRETUDE Injection, cabotegravir, 1 mg | Charles River Associates, Inc. Intramuscular | — | Establish | |
| J1306 | LEQVIO Injection, inclisiran, 1 mg | Novartis Subcutaneous | — | Establish | |
| J1551 | cutaquig Injection, immune globulin (cutaquig), 100 mg | Octapharma USA, Inc. Subcutaneous | — | Establish | |
| J2356 | TEZSPIRE Injection, tezepelumab-ekko, 1 mg | Amgen Subcutaneous | — | Establish | |
| J2779 | SUSVIMO Injection, ranibizumab, via intravitreal implant (susvimo), 0.1 mg | Genentech Intravitreal | ReplacesC9093 | Establish | |
| J2998 | RYPLAZIM Injection, plasminogen, human-tvmh, 1 mg | Kedrion Biopharma Inc. Intravenous | ReplacesC9090 | Establish | |
| J3299 | XIPERE Injection, triamcinolone acetonide (xipere), 1 mg | Bausch & Lomb | ReplacesC9092 | Establish | |
| J9331 | FYARROTM Injection, sirolimus protein-bound particles, 1 mg | Aadi Intravenous | ReplacesC9091 | Establish | |
| J9332 | VYVGART Injection, efgartigimod alfa-fcab, 2 mg | Ar genx Intravenous | — | Establish | |
| Q4259 | celera Celera dual layer or celera dual membrane, per square centimeter | Nvision Biomedical Technologies, Inc. | — | Establish | |
| Q4260 | Signature APatch Signature apatch, per square centimeter | Signature Biologics | — | Establish | |
| Q4261 | TAG Tag, per square centimeter | Conventus Flower Orthopedics | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, First Quarter 2022 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
